However, higher GLI-1 expression was associated with a non-significant trend toward extended PFI in non-TKI-treated patients (75.31 vs. 58.48 months), and also a significant extended PFI in TKI-treated lung cancer patients (41.25 vs. 31.10 months), showing that our in vivo model demonstrated a trend that diverges from the tendency observed in lung cancer patients with low MEOX2 versus low GLI-1 expression (Fig. 1E, F). The gene discussed is MEOX2; the disease is lung cancer.